The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...
The FDA expanded its approval of Addyi to treat low libido in postmenopausal women up to age 65. The approval will open up ...
The FDA is seeking feedback on whether — and how — to expand the number of men prescribed testosterone treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback